We are studying whether letermovir can better prevent CMV infection in lung transplant recipients compared to standard treatment with valganciclovir. This research may help improve care for patients at risk of CMV disease.
Health conditions and diseases that the clinical trial is designed to study and treat.
Lung transplant patients (D+/R-) are individuals who have received a lung transplant from a donor who is positive for certain viruses, while the recipient is negative. This group may face unique challenges in recovery and management of their health.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.